Hematology / Oncology @Point of Care Podcasts https://atpointofcare.com/our-apps/#Hematology Pinecast (https://pinecast.com) en-US@Point of Care @Point of Care atpointofcare@gmail.com false Hematology / Oncology @Point of Care Podcasts https://atpointofcare.com/our-apps/#Hematology https://storage.pinecast.net/podcasts/covers/54dff532-909d-4fc8-852b-66c58aef3572/HematologyOncology.png episodic Copyright 2020 At Point of Care, LLC. All rights reserved. https://pinecast.com/feed/oncology-point-of-care-podcast S34:E2 – Integrating Oral SERDs into the Management of HR+/HER2- Advanced Breast Cancer https://pinecast.com/guid/b8a1894c-a017-4c86-96a2-048600a21978 Tue, 22 Sep 2026 15:15:00 -0000 00:30:04 Explore the evolving role of oral SERDs in HR-positive, HER2-negative advanced breast cancer. Hear expert perspectives on ESR1 mutation testing, treatment selection and sequencing, emerging combination strategies, circulating tumor DNA (ctDNA) monitoring, and safety considerations that may inform individualized treatment decisions.

Visit https://suitehome.atpointofcare.com/library/2760.12/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Integrating Oral SERDs into the Management of HR+/HER2- Advanced Breast Cancer false 34 2 S34:E1 – ESR1 Mutations in Advanced Breast Cancer: The Evolving Role of Oral SERDs https://pinecast.com/guid/5b87af6e-dc20-4b0c-be3a-177932845736 Tue, 22 Sep 2026 15:00:00 -0000 00:29:09 https://suitehome.atpointofcare.com/library/2760.11/page/0 Stay ahead of evolving endocrine resistance in HR-positive, HER2-negative advanced breast cancer. Discover how ESR1 mutations are reshaping treatment decisions, and explore expert perspectives on mutation testing, oral SERDs, and emerging serial monitoring strategies that may help identify resistance earlier and inform individualized patient care.

Visit https://suitehome.atpointofcare.com/library/2760.11/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> ESR1 Mutations in Advanced Breast Cancer: The Evolving Role of Oral SERDs false 34 1 S33:E2 – Navigating the KRAS Pipeline: Clinical Implications for Pancreatic Cancer Care https://pinecast.com/guid/99a7614e-4d51-471d-b44f-01b0f5631d57 Wed, 09 Sep 2026 15:30:00 -0000 00:28:38 https://suitehome.atpointofcare.com/library/2746.02/page/0 RAS-targeted therapies are reshaping the treatment landscape for pancreatic ductal adenocarcinoma, creating new challenges in understanding the mechanisms and potential clinical applications of allele-specific, pan-KRAS, and pan-RAS inhibitors. Join Dr. Eileen O’Reilly and Dr. Margaret Tempero as they explore the evolving RAS therapeutic pipeline and discuss how these emerging strategies may inform future treatment decisions.

Visit https://suitehome.atpointofcare.com/library/2746.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Navigating the KRAS Pipeline: Clinical Implications for Pancreatic Cancer Care false 33 2 S33:E1 – Genomic Profiling in Pancreatic Cancer: From Guidelines to Practice https://pinecast.com/guid/2dfebf75-7391-490a-9905-f5cf9bf59f36 Tue, 08 Sep 2026 15:00:00 -0000 00:29:58 https://suitehome.atpointofcare.com/library/2746.01/page/0 As biomarker-directed therapies expand in pancreatic ductal adenocarcinoma, comprehensive genomic profiling is becoming increasingly important for identifying actionable alterations and informing treatment decisions. Join Dr. Eileen O’Reilly and Dr. Margaret Tempero as they discuss when and how to perform genomic profiling, interpret key findings, and address practical challenges to obtaining clinically useful molecular information.

Visit https://suitehome.atpointofcare.com/library/2746.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Genomic Profiling in Pancreatic Cancer: From Guidelines to Practice false 33 1 S32:E3 – Perioperative MIBC: Navigating the New Toxicity Management https://pinecast.com/guid/ee27ed70-28af-454d-a383-c4d7cd26f2e6 Sat, 15 Aug 2026 04:20:00 -0000 00:20:35 This final episode of a three-part expert-led podcast series explores the emerging toxicity landscape as immunotherapy- and antibody-drug conjugate–based regimens enter the treatment of muscle-invasive bladder cancer. Faculty will discuss the mechanistic basis for these side effects, practical monitoring and management strategies, and the multidisciplinary coordination needed among oncology, urology, and subspecialists to navigate them safely.

Visit https://suitehome.atpointofcare.com/library/2744.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Perioperative MIBC: Navigating the New Toxicity Management false 32 3 S32:E2 – Perioperative MIBC: Treatment Selection in Practice https://pinecast.com/guid/d400a77e-b0d8-4ec3-9b5c-9669663ea704 Sat, 15 Aug 2026 04:10:00 -0000 00:20:08 https://suitehome.atpointofcare.com/library/2744.02/page/0 This expert-led podcast explores practical treatment selection in the evolving perioperative landscape for muscle-invasive bladder cancer. Faculty will discuss how to assess treatment eligibility, navigate immunotherapy-based and antibody-drug conjugate–based options, and coordinate care across specialties to support timely, individualized treatment decisions.

Visit https://suitehome.atpointofcare.com/library/2744.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Perioperative MIBC: Treatment Selection in Practice false 32 2 S32:E1 – Perioperative MIBC: Translating Trial Into Practice https://pinecast.com/guid/faf5720b-ca00-4f86-a9d2-187fabc76711 Sat, 15 Aug 2026 04:00:00 -0000 00:17:57 https://suitehome.atpointofcare.com/library/2744.01/page/0 This expert-led podcast explores the rapidly evolving perioperative treatment landscape in muscle-invasive bladder cancer. Faculty will discuss pivotal data from NIAGARA, KEYNOTE-905, and KEYNOTE-B15, and consider how recent advances are expanding systemic treatment options, including for patients who are cisplatin-ineligible, and reshaping perioperative care.

Visit https://suitehome.atpointofcare.com/library/2744.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Perioperative MIBC: Translating Trial Into Practice false 32 1 S31:E2 – Matching Therapy to Biology: The Importance of PTCL Subtype https://pinecast.com/guid/c93818c6-05f9-4d79-b0cb-6fff03c28b7b Mon, 03 Aug 2026 04:10:00 -0000 00:23:34 https://www.atpointofcare.com/library/2736.02/page/0 Given the diversity of peripheral T-cell lymphoma (PTCL) subtypes, clinicians may need guidance choosing which therapy is most appropriate for each subtype. Join Dr. Steven Horwitz and Theresa Davey, PA-C, for a discussion of the PTCL treatment landscape and the evidence for matching epigenetic therapies to specific PTCL subtypes.

Visit https://www.atpointofcare.com/library/2736.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Matching Therapy to Biology: The Importance of PTCL Subtype false 31 2 S31:E1 – Emerging Evidence: What Clinical Trials Reveal About Epigenetic Therapies in PTCL https://pinecast.com/guid/73ff7c90-99bc-4938-a16b-c69759f55648 Mon, 03 Aug 2026 04:00:00 -0000 00:26:08 https://www.atpointofcare.com/library/2736.01/page/0 Relapsed/refractory peripheral T-cell lymphoma (PTCL) remains a significant treatment challenge. Join Dr. Stephen Horwitz and Theresa Davey as they review emerging clinical trial data on epigenetic therapies, including azacitidine, HDAC (histone deacetylase) inhibitors, and EZH (enhancer of zeste homolog)-targeted agents, and discuss how biology-driven treatment strategies may help personalize care and improve outcomes for patients with PTCL.

Visit https://www.atpointofcare.com/library/2736.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

]]> Emerging Evidence: What Clinical Trials Reveal About Epigenetic Therapies in PTCL false 31 1 S31:E3 – Personalizing Care With Factor VIIIa Mimetics for Patients With Hemophilia A https://pinecast.com/guid/2f3464ec-537a-4032-918e-4c9f45dde842 Fri, 24 Jul 2026 04:10:00 -0000 00:27:04 https://www.atpointofcare.com/library/2723.02/page/0 Join expert hematologists, Drs. Stacy Croteau and Guy Young, as they provide their expert opinion regarding strategies for personalizing care for patients with hemophilia A. Topics discussed in this podcast include an overview of the current and investigational therapeutic landscape and an in-depth dialogue where they review their shared decision-making strategies and best practices for individualized care in clinical practice.

Visit [https://www.atpointofcare.com/library/2723.02/page/0 ](

This podcast is powered by Pinecast.

]]> Personalizing Care With Factor VIIIa Mimetics for Patients With Hemophilia A false 31 3